Should I buy or sell Lexicon Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares. View LXRX analyst ratings or view top-rated stocks .

What is Lexicon Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for Lexicon Pharmaceuticals' shares. Their LXRX share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 206.7% from the stock's current price. View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts .

How have LXRX shares performed in 2024?

Lexicon Pharmaceuticals' stock was trading at $1.53 at the beginning of 2024. Since then, LXRX stock has increased by 6.5% and is now trading at $1.63. View the best growth stocks for 2024 here .

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our LXRX earnings forecast .

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Monday, March, 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. The biopharmaceutical company earned $0.70 million during the quarter, compared to analysts' expectations of $0.68 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 138.54% and a negative net margin of 14,573.20%.

What ETF holds Lexicon Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 293,092 shares of LXRX stock, representing 2.98% of its portfolio.

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com . Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA) , Sarepta Therapeutics (SRPT) , ACADIA Pharmaceuticals (ACAD) , Dynavax Technologies (DVAX) , MannKind (MNKD) , ImmunoGen (IMGN) , Geron (GERN) , Micron Technology (MU) , TherapeuticsMD (TXMD) and Gilead Sciences (GILD) .

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LXRX

Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free LXRX Stock Alerts

$1.63

+0.01 (+0.62%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.62
▼
$1.73
50-Day Range: $1.62
▼
$3.58
52-Week Range: $0.92
▼
$3.79

Volume: 3.71 million shs
Average Volume: 4.48 million shs
Market Capitalization: $401.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Lexicon Pharmaceuticals alerts:

Lexicon Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 206.7% Upside
$5.00 Price Target
Short Interest: Bearish
8.90% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.27
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.71) to ($0.66) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.93 out of 5 stars

Medical Sector

808th out of 918 stocks

Pharmaceutical Preparations Industry

355th out of 402 stocks

3.0

Analyst's Opinion

Consensus Rating
Lexicon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Lexicon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.90% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Lexicon Pharmaceuticals has recently increased by 2.62%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Lexicon Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Lexicon Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LXRX.

1.8

News and Social Media Coverage

News Sentiment
Lexicon Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Lexicon Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 18 people have searched for LXRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders.
Percentage Held by Institutions
74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.71) to ($0.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lexicon Pharmaceuticals is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lexicon Pharmaceuticals is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lexicon Pharmaceuticals has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

LXRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LXRX Stock News Headlines

April 18, 2024 | globenewswire.com

Lexicon Pharmaceuticals to Host 2024 Investor Day

April 16, 2024 | americanbankingnews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded by StockNews.com to Sell

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 13, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)

April 3, 2024 | finance.yahoo.com

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 25, 2024 | globenewswire.com

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

March 16, 2024 | finance.yahoo.com

LXRX Apr 2024 5.000 put

March 12, 2024 | seekingalpha.com

Lexicon stock slides 8% after rallying 30% in prior session

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 12, 2024 | markets.businessinsider.com

Lexicon Announces Positive Data Of InTandem3 Study In Type 1 Diabetes Patients With CKD; Stock Down

March 12, 2024 | finance.yahoo.com

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

March 12, 2024 | seekingalpha.com

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

March 11, 2024 | marketwatch.com

Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin

March 11, 2024 | finance.yahoo.com

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

March 11, 2024 | washingtonpost.com

Lexicon: Q4 Earnings Snapshot

March 11, 2024 | benzinga.com

Lexicon Pharmaceuticals: Q4 Earnings Insights

March 11, 2024 | globenewswire.com

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

March 11, 2024 | globenewswire.com

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

February 22, 2024 | finance.yahoo.com

15 Hot Penny Stocks On the Move

February 17, 2024 | finance.yahoo.com

LXRX Feb 2024 5.000 put

January 31, 2024 | fool.com

3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts

January 26, 2024 | seekingalpha.com

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

January 11, 2024 | finance.yahoo.com

Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48% ownership, institutions own 24%

January 8, 2024 | finance.yahoo.com

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

January 4, 2024 | seekingalpha.com

Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value

December 26, 2023 | fool.com

3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

December 21, 2023 | finance.yahoo.com

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

See More Headlines

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:LXRX
Previous Symbol: NASDAQ:LEXG
CUSIP: 52887210
CIK: 1062822
Web: www.lexpharma.com
Phone: (281) 863-3000
Fax: 281-863-8010
Employees: 285
Year Founded: 1995

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +197.6%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-177,120,000.00
Net Margins: -14,573.20%
Pretax Margin: -14,710.88%
Return on Equity: -138.54%
Return on Assets: -71.29%

Debt

Debt-to-Equity Ratio: 1.07
Current Ratio: 5.60
Quick Ratio: 5.58

Sales & Book Value

Annual Sales: $1.20 million
Price / Sales: 344.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.38 per share
Price / Book: 4.42

Miscellaneous

Outstanding Shares: 246,240,000
Free Float: 229,493,000
Market Cap: $413.68 million
Optionable: Optionable
Beta: 1.27

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Lonnel Coats (Age 59)
CEO & Director
Comp: $1.14M
Mr. Jeffrey L. Wade J.D. (Age 59)
President & CFO
Comp: $752.05k
Mr. Brian T. Crum (Age 51)
Senior VP, General Counsel & Secretary
Comp: $596.48k
Dr. Alan J. Main Ph.D. (Age 70)
Executive Vice President of Innovation & Chemical Sciences
Comp: $576.96k
Dr. Craig B. Granowitz M.D. (Age 59)
Ph.D., Senior VP & Chief Medical Officer
Comp: $652.48k
Ms. Kristen L. Alexander (Age 56)
Vice President of Finance & Accounting
Ms. Lisa M. DeFrancesco (Age 44)
Head of Investor Relations & Corporate Strategy
Mr. Dixon Terry
Vice President of Compliance
Ms. Carrie Siragusa
Vice President of Marketing
Ms. Desiree Gendron
Vice President of Sales & Training

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LXRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LXRX, but not buy additional shares or sell existing shares.
View LXRX analyst ratings or view top-rated stocks.
What is Lexicon Pharmaceuticals' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month target prices for Lexicon Pharmaceuticals' shares. Their LXRX share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 206.7% from the stock's current price.
View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts.
How have LXRX shares performed in 2024?: Lexicon Pharmaceuticals' stock was trading at $1.53 at the beginning of 2024. Since then, LXRX stock has increased by 6.5% and is now trading at $1.63.
View the best growth stocks for 2024 here.
When is Lexicon Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our LXRX earnings forecast.
How were Lexicon Pharmaceuticals' earnings last quarter?: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Monday, March, 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. The biopharmaceutical company earned $0.70 million during the quarter, compared to analysts' expectations of $0.68 million. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 138.54% and a negative net margin of 14,573.20%.

What ETF holds Lexicon Pharmaceuticals' stock?: Virtus LifeSci Biotech Products ETF holds 293,092 shares of LXRX stock, representing 2.98% of its portfolio.
What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?: 9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Lexicon Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).
How do I buy shares of Lexicon Pharmaceuticals?: Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LXRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial